July/August 2016

CATT 5-Year Data: Our Perspective

Allen C. Ho, MD, and Robert L. Avery, MD

News

Medical Update

Hacking the EpicCare Electronic Health Record System

How to make this widely used EHR system more efficient for high-volume vitreoretinal surgeons.

William J. Foster, MD, PhD, and David Fleece, MD

Visual Function Biomarkers Needed for Dry AMD

Early detection may allow treatment and possible reversal. Part 1 of a 2-part series.

Aron Shapiro

Building and Maintaining a Referral Base

Tips for newly graduated fellows.

Murtaza Adam, MD

A Potpourri of Complicated Surgical Coding Cases

These coding tips and examples can help minimize common problems related to claim denials.

Riva Lee Asbell

Macular Hole Repair Using an ILM Patch

Concept of ILM flap or patch for use in challenging cases.

Brian C. Joondeph, MD, MPS

Removal of Hydrogel Scleral Buckles

Surgery to remove these devices must involve caution due to risk of complications.

Niels Crama, MD

The Burden of Noninfectious Uveitis of the Posterior Segment: A Review

New pharmacologic treatment options are urgently needed.

Steven Yeh, MD, and Jessica G. Shantha, MD

Which Tumor, What Imaging Modality?

Play your cards right and make the best bet for tumor diagnosis.

Carol L. Shields, MD; Kareem Sioufi, MD; Timothy Fuller, MD; Timothy Higgins, BS; Sandor R. Ferenczy, CRA; and Jerry A. Shields, MD

Intraarterial Chemotherapy for Retinoblastoma

History, technique, and update on outcomes.

Ryan S. Kim, BA; Mark J. Dannenbaum, MD; and Amy C. Schefler, MD

Profile of a Medical Retina Specialist

Shedding light on a new breed of clinicians.

Jordana G. Fein, MD, MS, and Heeral R. Shah, MD

The Promise of Integrin Receptors for Treating Vitreoretinal Disorders

Study results suggest this class of drug has vitreolytic activity and a longer duration of effect than current treatments.

Victor H. Gonzalez, MD

The Role of Laser in the Pharmacologic Era of Retina

Laser still plays a prominent part in managing retinal pathologies, and innovations in laser delivery suggest potential areas where indications might be expanded.

Baruch Kuppermann, MD, PhD

An Oral Drug for Treatment of AMD?

The potential for this proposed treatment option could be significant for many patients and their caregivers.

Carl C. Awh, MD

Improving Outcomes in Neovascular AMD With Combination Intravitreal Therapy

Could an anti-PDGF drug work with an anti-VEGF agent to provide better antiangiogenic effect than anti-VEGF monotherapy?

Jeffrey S. Heier, MD

Combination Therapy for Neovascular AMD

Could the combination of an anti-VEGF agent and an anti-PDGF drug solve some of the issues seen with anti-VEGF monotherapy? Trial data may soon tell.

Glenn J. Jaffe, MD

Other Anti-VEGF/Anti-PDGF Combination Drugs in the Pipeline for Treatment of AMD

the staff of Retina Today

5Q With Ehsan Rahimy, MD

Ehsan Rahimy, MD, is a Surgical and Medical Vitreoretinal Specialist at the Palo Alto Medical Foundation in Palo Alto, Calif.

Anti-TNFα Agents

Eric Suhler, MD, MPH, and Thomas Albini, MD